Search

Guardant Health Inc

Cerrado

SectorSanidad

170.69 1.8

Resumen

Variación precio

24h

Actual

Mínimo

168.5

Máximo

170.69

Métricas clave

By Trading Economics

Ingresos

-8.1M

-120M

Ventas

33M

335M

BPA

-0.89

Margen de beneficios

-35.866

Empleados

2,490

EBITDA

-8.1M

-109M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+12.23% upside

Dividendos

By Acuity

Próximas Ganancias

28 oct 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

2.4B

22B

Apertura anterior

168.89

Cierre anterior

170.69

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

150 / 340 Clasificación en Healthcare

Guardant Health Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 ago 2026, 19:16 UTC

Guardant Health Inc shares are higher today, despite pulling back from an intraday high. The stock remains well above its 20-day moving average.

20 ago 2026, 23:46 UTC

Guardant Health Inc. shares advanced in after-market trading, remaining above their 20-day moving average amid broader market pressures from rising crude oil prices.

19 ago 2026, 20:02 UTC

Guardant Health Inc shares are higher today, supported by high trading volume. The stock remains above its 20-day moving average and near recent highs.

14 ago 2026, 19:36 UTC

Guardant Health Inc shares are lower amid broader market sentiment following disappointing retail sales data, which may impact consumer demand and Federal Reserve interest rate policy.

13 ago 2026, 23:36 UTC

Guardant Health shares are higher in after-market trading, though no specific news was identified. Broader market sentiment may be influenced by unchanged producer prices.

12 ago 2026, 19:51 UTC

News

Guardant Health shares are lower as insider sales raise investor concerns. Director Ian Clark sold 14,180 shares for $2.3 million earlier this month.

10 ago 2026, 19:36 UTC

Guardant Health Inc. shares are higher today, remaining above their 20-day moving average amid rising oil prices driven by geopolitical tensions.

7 ago 2026, 20:03 UTC

Guardant Health Inc shares are advancing amid strong momentum and high trading volume. Broader market gains coincide with a decline in Treasury yields.

6 ago 2026, 19:36 UTC

Guardant Health Inc shares are lower today, continuing a decline since Wednesday's close. No specific news was identified to explain the movement.

3 ago 2026, 19:56 UTC

News

Guardant Health shares are higher as Stifel and Canaccord maintain Buy ratings, raising price targets to $180 and $205, respectively.

31 jul 2026, 19:51 UTC

News
Social Media

Guardant Health Inc shares are trading higher as analysts raise price targets following strong second-quarter results and an upward revision of full-year revenue guidance.

30 jul 2026, 23:21 UTC

News
Social Media

Guardant Health reported second-quarter revenue of $335 million, raising 2026 guidance to $1.34 billion to $1.36 billion, boosting shares in after-market hours.

29 jul 2026, 18:54 UTC

Macro Event
News

Guardant Health Inc shares are higher as investors anticipate Q2 earnings on Thursday, following last quarter's revenue of $301.7 million, up 48.3% year-over-year.

28 jul 2026, 19:16 UTC

News

Guardant Health shares are lower despite a tribute video featuring Patrick Dempsey and RBC's note on potential coverage tailwinds for the company.

27 jul 2026, 19:36 UTC

News

Guardant Health Inc shares are lower, continuing a five-day decline despite a 48% year-over-year revenue increase and strong performance in the Shield segment.

24 jul 2026, 18:36 UTC

Guardant Health Inc shares are lower today, continuing a decline since Thursday's close and remaining below the 20-day moving average.

20 jul 2026, 20:02 UTC

News

Guardant Health Inc shares are lower today, continuing a decline since Friday amid mixed U.S. market performance and ongoing geopolitical tensions impacting investor sentiment.

Comparación entre iguales

Cambio de precio

Guardant Health Inc previsión

Precio Objetivo

By TipRanks

12.23% repunte

Estimación a 12 Meses

Media 191.56 USD  12.23%

Máximo 215 USD

Mínimo 125 USD

De acuerdo con 21 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Guardant Health Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

21 ratings

21

Comprar

0

Mantener

0

Vender

Sentimiento

By Acuity

150 / 340 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat